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Complement dysregulation is characteristic of the renal diseases atypical hemolytic
uremic syndrome (aHUS) and complement component 3 glomerulopathy (C3G).
Complement regulatory protein Factor H (FH) inhibits complement activity, whereas FH-
related proteins (FHRs) lack a complement regulatory domain. FH and FHRs compete for
binding to host cell glycans, in particular heparan sulfates (HS). HS is a glycosaminoglycan
with an immense structural variability, where distinct sulfation patterns mediate specific
binding of proteins. Mutations in FH, FHRs, or an altered glomerular HS structure may
disturb the FH : FHRs balance on glomerular endothelial cells, thereby leading to
complement activation and the subsequent development of aHUS/C3G. In this study,
we aimed to identify specific HS structures that could specifically compete off FHRs from
HS glycocalyx (HSGlx), without interfering with FH binding. FH/FHR binding to human
conditionally immortalized glomerular endothelial cells (ciGEnCs) and HSGlx purified from
ciGEnC glycocalyx was assessed. HS modifications important for FH/FHR binding to
HSGlx were analyzed using selectively desulfated heparins in competition with purified
HSGlx. We further assessed effects of heparinoids on FHR1- and FHR5-mediated C3b
deposition on ciGEnCs. In the presence of C3b, binding of FH, FHR1 and FHR5 to
ciGEnCs was significantly increased, whereas binding of FHR2 was minimal. FHR1 and 5
competitively inhibited FH binding to HSGlx, leading to alternative pathway dysregulation.
FHR1 and FHR5 binding was primarily mediated by N-sulfation while FH binding
depended on N-, 2-O- and 6-O-sulfation. Addition of 2-O-desulfated heparin
significantly reduced FHR1- and FHR5-mediated C3b deposition on ciGEnCs. We
identify 2-O-desulfated heparin derivatives as potential therapeutics for C3G and other
diseases with dysregulated complement.
Keywords: complement, factor H (FH), factor H-related protein, heparan sulfate (HS), heparin, complement
3 glomerulopathy
Frontiers in Immunology | www.frontiersin.org August 2021 | Volume 12 | Article 6766621
Edited by:
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INTRODUCTION
The complement system serves an important role in immunity by
removing pathogens and apoptotic debris. Three distinct pathways
can induce complement activation, with the alternative pathway
(AP) targeting both pathogens and host tissues. Complement
activation results in the cleavage of complement component C3
to C3b, which attaches covalently to cell surfaces and extracellular
matrix. C3b recruits complement factor B to form a catalytic
complex called C3 convertase that results in feed-forward
amplification of complement activation, culminating in the
formation of the lytic pore C5b-9 complex (1).
Failure to control AP activation on host tissues can lead to
disease, including the glomerular diseases complement
component 3 glomerulopathy (C3G) (2) and atypical
hemolytic uremic syndrome (aHUS) (3). C3G and aHUS have
been associated with genetic variations in various complement
genes, including complement factor H (CFH), which encodes
Factor H (FH) the main inhibitor of the AP (4). FH, which
consists of 20 homologous complement control protein (CCP)
domains, binds to C3b (5) to displace factor B (decay accelerating
activity, DAA) (6) and it also acts as cofactor for complement
factor I-mediated cleavage of C3b into iC3b (cofactor activity)
(7). FH differentiates between host tissues and pathogens by
binding to heparan sulfate (HS) on host tissues using CCP7 (8, 9)
and CCP20 (10), and to sialic acid using CCP20 (11).
FH-mediated complement control is further modulated by six
FH-related proteins (FHR1-3, 4A, 4B and 5) which contain CCPs
with high homology to many but not all CCPs of FH. Notably the
N-terminal complement regulatory domain present in FH is
absent in FHRs. CCPs in FHR proteins that are homologous to
CCP7 and CCP19-20 in FH facilitate FHR binding to FH ligands,
including HS and C3b (12–14). FHRs have therefore been
proposed to compete with FH for ligands on host tissues such
as glomerular endothelial cells and the glomerular basement
membrane, potentially leading to local dysregulation of AP
activation and tissue damage (15).
FHRs can be divided into type 1 FHRs (FHR1, FHR2, and
FHR5), which occur as homo- and heterodimers, and type 2
FHRs (FHR3, FHR4A, and FHR4B), which are monomeric in
plasma (16, 17). Type 1 FHRs, particularly FHR1 and FHR5, are
prominently found in renal biopsies of C3G patients (18). In
addition, in both aHUS and C3G patients, pathologic type 1 FHR
gene rearrangements have been described that generate novel
FHRs proteins with increased abilities to compete with FH for
cell surface and extracellular matrix binding (15, 19, 20).
We hypothesized that pathogenic changes, for example
genetically inherited, or induced by infections or high blood
pressure, in glomerular tissues, e.g. deviations in the HS
structures, may also affect the balance between FH and FHR
binding, thereby further contributing to disease development.
HS is a linear polysaccharide from the glycosaminoglycan family
that is particularly prominent in the endothelial glycocalyx, a thick
glycan layer lining the lumen of blood vessels (21). HS is synthesized
by a complex biomachinery that involves more than 30 enzymes
(22). Initially, a carbohydrate backbone is generated by the action of
exostosin 1/exostosin 2 (EXT1/2) copolymerase that adds up to 100-
200 repeating units of the glucuronic acid-N-acetylglucosamine
(GlcA-GlcNAc) disaccharide motif. Subsequently, N-deacetylase/
N-sulfotransferases (NDSTs) substitute acetyl groups in GlcNAc
residues for sulfates, the first of several different sulfate
modifications. GlcA can be converted to iduronic acid (IdoA) by
glucuronic acid epimerase (GLCE), introducing additional
structural variability (23). Finally, sulfate modifications are added
by sulfotransferases (HS2STs, HS3STs, and HS6STs) at the 2-O-
position of GlcA/IdoA and the 3-O- and/or 6-O-positions,
respectively, of GlcNAc/GlcNS. The number of structural
possibilities within an HS chain is immense; considering 48
possible disaccharides, regarding possible combinations of
modifications, an average HS chain of 100 disaccharides has 48100
which equals 10168 possible structures. The structural diversity of
HS, mainly dictated by distinct sulfation patterns, explains why HS
mediates the specific binding and function of a myriad of proteins,
including complement proteins (24, 25). Notably, heparin and
highly sulfated domains within HS are similar, whereas heparin
overall is more sulfated than HS.
While the cell surface recognition domains of FH and FHRs
are highly homologous, they are not identical. It is known that
small changes in the HS binding domains of FH significantly
affect the specificity of protein interaction with certain sulfate
modifications (26), and therefore it is reasonable to hypothesize
that similar differences in specificity may exist between FH and
FHRs. Theoretically, the relative binding affinities of FH and
FHR to host tissues, i.e. endothelial glycocalyx, may be different,
which could be selectively inhibited by HS or heparinoid
oligosaccharides. Therefore, in this study, we sought to
investigate whether HS structures can be identified, which
differentially alter FH and/or FHR binding to the glycocalyx of
glomerular endothelial cells. Indeed, we found that binding of
FH, FHR1 and FHR5 proteins to glomerular endothelial HS is
differentially mediated by N-, 2-O- and 6-O-sulfation. These
findings offer novel insights into the underlying pathophysiology
of C3G and may lead to novel treatments for C3G and other
diseases with dysregulated complement activity.
MATERIALS AND METHODS
Participants
Patients with C3G referred to the Molecular Otolaryngology and
Renal Research Laboratories (MORL) at the University of Iowa
(UI) for a genetic evaluation of complement genes were enrolled
in this study. C3G was diagnosed by the presence of C3 deposits
by immunofluorescence in the absence, or comparatively reduced
presence of other immunoreactants (C3 immunofluorescence at
least two orders of magnitude greater intensity than for any other
immunoreactant). Copy number variation in the CFH-CFHR
genomic region was determined using multiplex ligation-
dependent probe amplification. The study was approved by the
Institutional Review Board of Carver College of Medicine at the
University of Iowa.
Cell Culture
Conditionally immortalized human glomerular endothelial cells
(ciGEnCs) were cultured as previously described (27) on 1.0 µg/cm2
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bovine fibronectin (Bio-Connect BV, Huissen, The Netherlands)
coating. For proliferation, cells were cultured at 33°C in endothelial
cell basal medium (EGM-2 MV; Lonza, Verviers, Belgium). For
experiments, ciGEnCs were seeded at 25% confluence at 37°C and
grown to confluent monolayers. Human umbilical vein endothelial
cells (HUVECs) were cultured as previously described (28). Media
were refreshed every two days.
Evaluation of FH/FHR ciGEnC Binding
Using ELISA
ciGEnCs were differentiated in 96 well plates for five days. After
differentiation, cells were washed twice using Hank’s balanced salt
solution includingMg2+/Ca2+ (HBSS) and incubated for 30 minutes
at RT with two-fold dilution series of serum-purified FH
(Complement Technologies Inc., Tyler, TX, USA) or recombinant
6xHis-tagged FHR1, FHR2 and FHR5 (Novoprotein, Summit, NJ,
USA) in HBSS with 2% (w/v) bovine serum albumin (BSA; Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands). Binding was
detected using monoclonal anti-FH antibody (Clone: Ox24; Bio-
Rad) followed by goat anti-mouse IgG1:horseradish peroxidase
(HRP) conjugate (Sanbio BV, Uden, The Netherlands), or mouse
anti-6xHis antibody (Sigma-Aldrich) followed by goat anti-mouse
IgG : HRP conjugate (Jackson ImmunoResearch, West Grove, PA).
Assays were developed using 3, 3’, 5, 5’ tetramethyl benzidine
substrate A+B (Biolegend, London, UK). Based on the titrations,
FH, FHR1, FHR2 and FHR5were used at a concentration of 100, 70,
50 and 10 µg/ml for all subsequent assays, unless stated otherwise.
For evaluation of FH and FHR binding to C3b-labeled
ciGEnCs, cells were cultured in 96 well plates for five days at
37°C, washed twice with HBSS and sensitized with anti-Jurkat/
Ramos/THP-1 antiserum (1:30 in HBSS) (29). Classical pathway
activation was then induced by incubation with 3.60 µg/ml C1,
1.00 µg/ml C2, 6.00 µg/ml C4 and 130 µg/ml C3 (Complement
technologies Inc.) in HBSS for 20 minutes at 37°C. C3b labeling
was confirmed using polyclonal sheep anti-C3 antibody (ICL
Inc., Portland, OR, USA) followed by rabbit anti-sheep IgG: HRP
conjugate (Sanbio BV). For competition assays between FH and
FHRs on C3b-labeled ciGEnCs, ciGEnCs were preincubated with
FHRs for 10 minutes before addition of FH for 20 minutes at RT.
Binding of FH and FHRs to C3b-labeled ciGEnCs was
determined as described above.
Alternative/Terminal Pathway
Activation Assays
ciGEnCs and HUVECs were cultured in 24 or 48 well plates as
described above. After differentiation, cells were washed twice
with 0.2% (w/v) BSA in phosphate-buffered saline (PBS) and
incubated for 30 minutes at 37°C with 20% (v/v) normal human
serum (NHS; Complement Technologies Inc., Tyler, TX, USA)
in veronal-buffered saline [15 mM barbitone, 145 mM NaCl,
5 mMMgCl2, 5 mM EGTA, 0.025% NaN3 (pH 7.3)] or 20% NHS
supplemented with 35 µg/ml FHR1, 25 µg/ml FHR2 or 5 µg/ml
FHR5 in veronal-buffered saline. 20% NHS supplemented with
10 mM EDTA was used to correct for cell surface binding of C3
in absence of complement activation. Monoclonal antibodies
specific for decay-accelerating factor (Bio-Rad Laboratories BV,
clone: BRIC-216) or membrane cofactor protein (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, clone: M177) were
included to sensitize ciGEnCs to AP activation. To determine
AP dysregulation on ciGEnCs in patient serum, cells were
incubated with C3G patient sera including: patients with 3 to 4
copies of the CFHR1 gene, the CFHR1 and CFHR3 gene deletion
(DCFHR3-CFHR1), 402H/H or 402Y/Y haplotype. Since C3G
patient sera samples were depleted of C3, the sera were
supplemented with either 20% NHS or C3 (130 µg/ml), factor B
(21 µg/ml) and factor D (0.2 µg/ml) (Complement Technologies
Inc.) before addition to the cells. Patient sera samples that did not
exceed the C3 signal of NHS supplemented with EDTA (MFI:
54819 ± 6202) by at least 2.5-fold after AP supplementation were
rejected from analysis. To determine potential therapeutic effects,
FHR-supplemented sera were spiked with 2-O-desulfated heparin
(oligosaccharides) before addition to the cells. Cells were detached
by incubationwith1%(w/v)BSA innon-enzymaticcelldissociation
solution (Sigma-Aldrich Chemie) and gentle scraping, centrifuged
at 500g and resuspended in 0.5% (w/v) BSA in ice-cold PBS. C3 and
C9 deposition was detected using polyclonal sheep anti-C3
antibodies and goat anti-C9 antiserum (Quidel, San Diego, CA,
USA). Antibody binding was quantified with Alexa 488-labeled
donkey anti-sheep IgG and donkey anti-goat IgG (Life
Technologies, Breda, The Netherlands) using a Beckman Coulter
CytoFLEXflowcytometerwithKaluza 2.1 software. Todetermine if
the classical pathway contributes to the observed C3b deposition,
cells were sensitizedwith anti-Jurkat/Ramos/THP-1 antiserum and
incubated with 20%NHS in either veronal-buffered saline orHBSS
(Supplementary Figure 1). To validate the flow cytometry assay
used to analyze C3b deposition, C3b deposition was also analyzed
using SDS PAA gel electrophoresis and Western blotting.
Heparan Sulfate Purification Using Low
Melting Agarose Barium Acetate Agarose
Gel Electrophoresis
Glycosaminoglycan extractions were performed as described
previously (30). GAGs were loaded on 1% (w/v) low-melting
agarose gel (Boehringer Mannheim, Mannheim, Germany), and
resolved by gel electrophoresis in 50 mM barium acetate buffer,
pH 5.0 (Sigma-Aldrich). Gels were stained using Azure A
(Sigma-Aldrich) and ciGEnC glycocalyx-derived HS (HSGlx)
bands were collected and melted at 65°C for 10 minutes. After
extraction using an equal volume basic phenol (Boom BV,
Meppel, The Netherlands), HSGlx in the aqueous phase was
collected and HSGlx was precipitated by addition of 0.24 µl
27% (w/v) sodium acetate (Sigma-Aldrich) and 3.72 µl ethanol
(Merck, Darmstadt, Germany) per µl aqueous phase, followed by
overnight incubation at -20°C. Precipitates were collected by
centrifugation at 15,700g for 10 minutes and resuspended in




2-O-desulfated heparin was generated from 100 mg heparin
(Aspen Oss BV, Oss, The Netherlands) as described previously
(31). A 5% (w/v) solution of heparin in H2O was alkalized
by adding sodium hydroxide (Merck) to 0.5 M concentration,
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snap-freezing and lyophilization. 1% (w/v) sodium borohydride
(Sigma Aldrich) was included to minimize degradation by
b-elimination. The resulting product was dissolved and
neutralized by adding 5% (v/v) acetic acid and dialyzed
extensively against H2O. Selective 2-O-desulfation was
confirmed by disaccharide analysis of 4 mg heparin or 2-O-
desulfated heparin as described previously (32). 2-O-desulfated
heparin oligosaccharide libraries were generated following the
protocol described by Powell et al. (33). 40 mg 2-O-desulfated
heparin were digested overnight at 37°C using 1.0 mU/mg
heparinase II (Iduron, Macclesfield, UK) in 2.0 ml 100 mM
acetate (pH 7.0), 1.5 mM calcium chloride. 5.00 to 8.75 mg/
separation of 2-O-desulfated heparin digest were resolved by size
exclusion chromatography in 0.25 M ammonium bicarbonate at
0.22 mL/min flow speed over a BioGel P10 column (75 x 1.6 cm;
Bio-Rad Laboratories BV) while monitoring the absorbance at
232 nm and collecting 1.0 mL fractions. Fractions corresponding
to defined peaks were pooled, dialyzed against H2O using 100-
500 Da molecular weight cut-off Float-A-Lyzers (Repligen,
Breda, Netherlands) and then concentrated by centrifugal
evaporation. 2-O-desulfated heparin oligosaccharides were
quantified using a Smart-Spec Plus spectrophotometer (Bio-Rad
Laboratories BV) to measure the absorbance 232 nm and an
extinction coefficient of 5500 M-1cm-1 (34). Successful digestion
and size separation were confirmed using polyacrylamide gel
electrophoresis compared to Arixtra, (GlaxoSmithKline,
Brentford, UK) and size-defined heparin oligosaccharide
standards (gifted from Prof. Jerry Turnbull’s lab) (33) and silver-
staining following Morrissey (35).
Competition Assays Using Selectively
Desulfated Heparin (Oligosaccharides)
HSGlx was immobilized on microtiter plates (NUNC, Roskilde,
Denmark) at a concentration which resulted in ~70% of the
EW4G2 (anti-HS antibody) signal obtained from 1.0 µg/well of
heparan sulfate from bovine kidney (Sigma-Aldrich). Plates were
washed using PBS/0.05% Tween-20 and blocked using 2% BSA
in HBSS for 2 hours at RT. Binding of FH, FHR1, FHR2 and
FHR5 after 1 hour incubation at RT was determined as described
for cell surface binding assays. For competition between FH and
FHRs, plates were preincubated with FHR1 or FHR5 in 2% BSA
in HBSS for 1 hour at RT before incubation with FH. The role of
HS modifications was evaluated by preincubating FH, FHR1 and
FHR5 with 100 µg/ml heparin, N-, 2-O- and 6-O-desulfated
heparin (Iduron, UK) for 1 hour at RT before addition to
immobilized HSGlx. To determine the minimum oligosaccharide
size required for inhibition of FHR1 and FHR5 binding to HSGlx,
proteins were preincubated with 10 µM of the different size
exclusion chromatography fractions.
Statistics
Groups were compared with Student’s unpaired t-test or One-
way ANOVA (>2 groups) followed by Tukey’s post-hoc test using
GraphPad Prism 9.1.2 (GraphPad Software Inc., San Diego, CA).
Values are given as mean ± standard error of the mean unless
stated otherwise. Statistical significance was accepted for p≤ 0.05.
RESULTS
FH and Type 1 FHRs Bind to (C3b-Labeled)
Glomerular Endothelial Cells In Vitro
To investigate the role of specific HS/heparinoid sulfate
modifications in the interaction between FH, type 1 FHRs and
HS in the glomerular endothelial glycocalyx in vitro, we first
evaluated the binding characteristics of FH and FHRs to
ciGEnCs. All proteins, except FHR2, bound to the cell surface
within their reported physiological concentrations (13, 36, 37)
(Figures 1A–D). Notably, since FHR2 hardly binds to ciGEnCs,
we mainly focused on FHR1 and FHR5 in our subsequent
experiments. Next, we wondered whether the presence of C3b
would influence FH and FHRs binding. To this end, we deposited
C3b on antibody-sensitized ciGEnCs using classical pathway
proteins (Supplementary Figure 1 and Figure 1E), which
significantly increased binding of FH and FHRs, though FHR2
binding remained relatively weak compared to FHR1 and FHR5
(Figure 1F and Supplementary Figure 2A).
FHR1 and FHR5 Cause Complement
Activation on Glomerular Endothelium
In Vitro
Next, we evaluated the effect of FHRs on complement regulation
on ciGEnCs. Supplementing human serum with FHR1, FHR2 or
FHR5 before incubation with ciGEnCs revealed significant
dysregulation of AP activity, as measured by increased C3b
deposition, in the case of FHR1 and FHR5 (Figure 2A and
Supplementary Figure 2B), and the terminal pathway activity,
as measured by C9 deposition, in the case of FHR1 (Figure 2B
and Supplementary Figure 2C). Furthermore, when ciGEnCs
were incubated with serum from C3G patients, significant
dysregulation of AP activity was observed (p=0.0011)
compared to healthy control serum (Figure 2C). Notably, to
validate our flow cytometry assay to measure C3b deposition, we
also analyzed C3b deposition in resolved cellular extracts
followed by Western blotting, which essentially yielded
quantitatively similar results (Supplementary Figure 3). To
determine if the observed dysregulation of the AP by the
added FHRs results from decreased FH binding to ciGEnCs,
FH was added to cells after incubation with FHRs. While no
significant inhibition of FH binding was observed on untreated
ciGEnCs, FHR5 significantly reduced cell surface binding of FH
after ciGEnCs were labeled with C3b using the classical pathway
proteins (Figure 2D and Supplementary Figure 2D). Thus,
HS-binding of type 1 FHRs deregulates complement activity on
ciGEnCs, which may depend in part on C3b deposition.
FHR1 and FHR5 Compete With FH for
Binding to HS Purified From Glomerular
Endothelial Glycocalyx (HSGlx)
Since cells express other potential ligands for FH/FHR than only
HS, we zoomed in on the interaction of FH and FHRs proteins
with purified HS isolated from glycocalyx (HSGlx) of cultured
glomerular endothelial cells. FH and FHRs binding to purified
and immobilized HSGlx revealed similar results as for binding to
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ciGEnCs, i.e. FH, FHR1 and FHR5 bound to HSGlx, whereas
FHR2 did not (Figure 3A and Supplementary Figure 2E).
Moreover, FHR1 and FHR5 efficiently competed with FH for
binding to HSGlx, since FH binding was reduced by the addition
of FHR1 or FHR5 (Figure 3B).
2-O-Desulfated Heparin Oligosaccharides
Selectively Inhibit FHR1 and FHR5
Binding, and Reduce C3b Deposition
on Endothelial Cells
To identify the nature of the HS structures in purified HSGlx that
are important for FH and/or FHR binding, we performed
competition assays with heparin and N-, 2-O- or 6-O-de-
sulfated heparins. Unmodified heparin blocked HS binding sites
on FH, FHR1 and FHR5, thereby reducing (for FH) or preventing
(for FHR1 and FHR5) binding to HSGlx, (Figures 3C–E).
Removing any of the sulfates from heparin largely abolished the
competition for FH binding to HSGlx (Figure 3C). In contrast, 2-
O- and 6-O-desulfated, and to a lesser degree, N-desulfated
heparin, were still able to compete for FHR1 (Figure 3D) and
FHR5 (Figure 3E). These results reveal that there is selectivity in
binding of FH versus FHR1/FHR5 to structures within HSGlx.
Importantly, C3b deposition by patient sera on ciGEnC was




FIGURE 1 | Factor H and recombinant FHR1 and FHR5 bind to glomerular endothelial cells in vitro. Factor H-related proteins (FHRs) 1 (A), 2 (B) and 5 (C) and
factor H (D) were titrated on conditionally immortalized glomerular endothelial cells (ciGEnCs) and binding was determined using ELISA. Labeling antibody-sensitized
ciGEnCs with C3b using classical pathway proteins (n=7) (E) significantly increased binding of factor H and FHR1 and FHR5 (n=3) (F). (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 vs Unlabeled).
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heparin, thereby suggesting that 2-O-desulfated heparin has
therapeutic value for complement-mediated glomerular disease
(Figure 3F). Addition of 2-O-desulfated heparin to FHR-
supplemented serum reverse the C3b deposition caused by
FHR1 competition with FH on ciGEnCs (Supplementary
Figure 4) as well as on HUVECs (Supplementary Figure 5) in
a concentration-dependent manner. Considering the highly
heterogenous structure of HS and heparin, associated with
many functions, a possible therapeutic should be preferably of
short length whilst retaining the functional activity. Therefore, to
determine the minimal size of 2-O-desulfated heparin required
for restoring complement regulation, a size-defined library of
oligosaccharides was generated from 2-O-desulfated heparin
(Supplementalry Figure 6 and Supplementary Table 1).
Addition of size-defined 2-O-desulfated fractions revealed that a
minimum of a tetrasaccharide (dp 4) was required for significant
binding toFHR1andFHR5 in competitionwithHSGlx (Figure4A),
thereby reducing FHR binding to glomerular endothelial cells
(Figure 4B). Importantly, FH binding to HSGlx was not altered by
any of the fractions tested (Figure 4A). Thus, 2-O-desulfated
heparin oligosaccharides were identified as highly selective
competitors reducing/preventing FHR1 and FHR5 binding to
HSGlx, but not affecting FH binding to HSGlx, thereby supporting
their potential application in novel C3G therapies.
DISCUSSION
The pathogenesis of C3G is driven by dysregulation of AP
complement activity in the fluid phase and/or glomerular
microenvironment. The relative balance between FH and type
1 FHR proteins is especially relevant in the glomerulus, as the
latter compete with the former for host tissue-associated ligands,
thereby affecting the relative degree of complement control in
this microenvironment. One of the most important host ligands
for FH and FHRs on glomerular endothelial cells is HS (36, 37).
In this study,we found thatwhile FH,FHR1 andFHR5bound to
ciGEnCs, the initial deposition of C3b significantly increased this
binding. The biggest relative changes were observed for FHR5, the
binding of which significantly reduced binding of FH, creating a
microenvironment inwhichAPactivitywas dysregulated, although
terminal pathway activity was not observed. FHR1, in contrast, did
not inhibit FH binding to ciGEnCs but nevertheless did lead to
dysregulated AP activity and activation of the terminal pathway.
A B
C D
FIGURE 2 | Factor H-related proteins 1 and 5 deregulate alternative pathway activation on glomerular endothelial cells in vitro. ciGEnCs were incubated in 20%
normal human serum (NHS) in veronal-buffered saline including 5 mM magnesium-EGTA, which prevents classical/lectin pathway activation. Serum was
supplemented with factor H-related proteins (FHRs) 1 or 5 and effects on alternative pathway (n=3) (A) and terminal pathway (n=3) (B) activity were evaluated using
flow cytometry. ciGEnCs were incubated with NHS or C3G patient sera (n=4, healthy controls; n=22, C3G patients) (C), including patients: with 3 to 4 copies of the
FHR1 gene (pink), FHR1 and FHR3 deletion (DCFHR3-1) (red), 402H/H haplotype (grey square) and 402Y/Y haplotype (grey circle). Sera were supplemented with
C3, factor B and factor D to ensure the presence of sufficient amounts of AP components. To determine the effect of FHR competition on FH binding, unlabeled or
C3b-labeled ciGEnCs were pre-incubated with buffer (Control) or FHRs 1 or 5, after which FH binding was detected using ELISA (n=4) (D). (*p < 0.05, **p < 0.01,
****p < 0.0001 vs NHS; ###p < 0.001 vs Control).
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FHR1-mediated dysregulation therefore may differ on cell surfaces
that have been C3b-labeled as compared to cell surfaces on which
C3 convertase has already formed. This difference suggests that
FHR1 may support the formation of C3 convertase, as has been
described for properdin (38, 39). Of note, we found that FHR2,
which is also a type 1 FHR, hardly bound to ciGEnCs.
Consistent with the results we observed with FHR1 and
FHR5, we also measured a significant increase in AP activity in
the sera of C3G patients, including patients with 3 or 4 copies of
the CFHR1 gene. This increase in AP activity was not seen in
C3G patients with DCFHR3-CFHR1 deficiency. These findings
suggest that in addition to fluid-phase dysregulation of the AP,
which is characteristic of C3G, dysregulation of complement can
also occur in the glomerular microenvironment and is impacted
by the relative levels of FH and FHR1/FHR5 in the circulation.
To further clarify the importance of HS modifications, we
studied the interaction between FH, FHRs and HS using purified




FIGURE 3 | O-desulfated heparins reduce FHR1 and FHR5 binding to purified glomerular endothelial glycocalyx-derived heparan sulfate (HS), without affecting FH
binding. HS was purified from isolated glycocalyx from conditionally immortalized glomerular endothelial cells (HSGlx) and immobilized on microtiter plates. Binding of
factor H (FH) and factor H-related proteins (FHRs) was measured using ELISA (n=4) (A). For competition assays, HSGlx was incubated with FHR1 or FHR5 before
binding of FH was determined (n=3) (B). The contribution of specific sulfate modifications to HSGlx binding of FH (n=3) (C), FHR1 (n=3) (D) and FHR5 (n=3) (E) was
evaluated by preincubating proteins with buffer (Control), heparin or 2-O-, 6-O- and N-desulfated (deS) heparin before addition to microtiter plates. To investigate
potential therapeutic effects of 2-O-desulfated heparin in context of C3G patient sera (402H/H haplotype group with >1.5x increased C3 deposition compared to
NHS), sera were supplemented with 50 µg/ml 2-O-desulfated heparin before addition to the cells (n=4) (F). (*p < 0.05, **p < 0.01, ****p < 0.0001 vs Control; ##p <
0.01, ####p < 0.0001 vs Heparin; ***p<0.001 vs C3G sera.)
Loeven et al. Targeting FHR Proteins in C3G
Frontiers in Immunology | www.frontiersin.org August 2021 | Volume 12 | Article 6766627
experiments, we compared heparin and HSGlx and found that the
former competed more efficiently for FHR1 and FHR5 than for
FH. Selectively desulfated heparin did not influence binding of
FH to HSGlx, which shows that binding of FH to HSGlx depends
on N-, 2-O- and 6-O-sulfation. These results match previous
reports involving FH-competition experiments with selectively
desulfated heparins (9, 40). Selectively desulfated heparins were
successful in preventing or reducing binding of FHR1 and FHR5
to HSGlx, except for N-desulfated heparin that still allowed FHR1
binding, which shows that FHR1 binding is primarily mediated
by N-sulfation.
Notably, although FHR5 bound more strongly to HSGlx as
compared with FHR1, FHR1 was the more potent competitor for
FH binding to HSGlx. This difference between FHR1 and FHR5
reflects the close homology between the HS binding domains of
FHR1 (CCP5) and FH (CCP20), which share 97% identity. The two
variant amino acids–L290 vs S1191 and A296 vs V1197–in FH and
FHR1 are buried and therefore unlikely to interact directly with HS.
They do however affect the structure of the surface-exposed loop that
harbors the HS-binding amino acids K285/K1186 and K287/K1188
in FHR1 and FH, respectively (41), possibly altering surface charge
distribution and consequently the HS binding characteristics of the
domain. This remarkable degree of ligand specificity is also seenwith
age-related macular degeneration and the associated p.Tyr402His
polymorphism (rs1061170) inCCP7of FH,which affects FHbinding
to specific HSmodifications in Buch’s membrane and is a risk factor
for disease (26). Type 1 FHRs (FHR1, 2 and 5) can also exist as
heterodimers or homodimers, which we have not addressed in this
study. However, we do not consider this as a major limitation, since
homodimers of FHR1, 2 and 5may have formed in our assays. Most
likely, our primary finding that 2-O-desulfated heparin can prevent
binding of FHR1 and FHR5 is also valid for heterodimers, since the
monomers present in a heterodimer bothwill bind to 2-O-desulfated
heparin, whereas FHR2 hardly binds to HSGlx.
The ability of 2-O-desulfated heparin oligosaccharides to
compete for FHR but not FH and thereby alter binding to HSGlx
suggests that providing a “sink” to scavenge FHR proteins
represents a novel treatment approach for C3G. 2-O-desulfation
by alkaline lyophilization is not only remarkably selective and
simple, but it also removes the rare glucosamine 3-O-sulfate
modification, which significantly reduces the anticoagulant
activity of 2-O-desulfated heparin (42) and thus potential adverse
effects.Weobserved that selective competition is retainedwith short
2-O-desulfated oligosaccharides (≥tetrasaccharides), potentially
enabling the synthesis of therapeutically active oligosaccharides
by chemoenzymatic methods (43).
In conclusion, we have demonstrated HS-mediated ligand
specificity for FH and FHR1/FHR5 that impacts the relative
balance of these proteins in the glomerular glycocalyx, thereby
altering AP regulation in this microenvironment. These results
A
B
FIGURE 4 | 2-O-desulfated heparin fragments with a size equal to or larger than tetrasaccharides reduce FHR1 and 5 binding to purified glomerular endothelial
HSGlx and ciGEnCs, without affecting FH binding to HSGlx. To determine the minimal oligosaccharide size required for FHR1 and FHR5 competition, proteins were
preincubated with equimolar amounts of 2-O-desulfated heparin digest size exclusion chromatography fractions (n=2) (A). Addition of 2-O-deS heparin or short 2-O-
deS oligosaccharides (Fraction8) to FHR-supplemented serum significantly reduced FHR binding to ciGEnCs (n≥2) (B). (*p < 0.05, **p < 0.01, ***p < 0.001 vs Control).
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provide novel insights into the pathophysiology of C3G and
suggest that genetic studies of C3G cohorts can identify patients
with variants in genes involved in HS proteoglycan synthesis that
create a “permissive” microenvironment, which favors FHR
binding over FH binding. This imbalance, in turn, supports
complement dysregulation either primarily or after secondary
triggering events. Our data also suggest a novel treatment for
C3G in which short 2-O-desulfated heparin oligosaccharides are
used to scavenge FHR1 and FHR5, thereby altering the binding
of these proteins to the glomerular glycocalyx (Figure 5).
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